Immunõ 2026: Where Is Cancer Immunotherapy Heading Next?
Sep 19, 2026
View online
Immunõ 2026: Where Is Cancer Immunotherapy Heading Next?
Highlights from SIOP 2026
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer After Endocrine Therapy
Robin Zon: ASCO Highlights Medicaid Policy Changes and Continuity of Cancer Care
ESMO Introduces 34 Social Media Ambassadors for ESMO Congress 2026
WHO Flags Six Essential Childhood Cancer Medicines Facing Critical Access Gaps
100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond
1 in 4 UK Royal Cancer Stories Contained Alarming Misinformation, Study Finds
The Voice of Oncology
Unsubscribe
|
Manage subscription
OncoDaily, P53 Inc.
867 Boylston Street, 5th Floor, Suite 1094, Boston, MA 02116
Copyright (C) 2023-2026. OncoDaily, P53 Inc. All rights reserved.
